Results, forecasts and guidance revisions from Japan's listed companies, in English.
Kaken's half-year operating profit rose to ¥10.16bn from ¥180mn, which the company attributes mainly to a $70mn Johnson & Johnson milestone, while Jublia's German launch via Almirall marks its first product rollout in Europe.
Leqembi sales rose 49.7% to ¥61.5bn in Eisai's first half, with the US self-injector IQLIK launched in August and full-year guidance of ¥70bn operating profit left unchanged.
Kyorin Pharmaceutical's operating guide swings from a ¥2bn profit to a ¥4.9bn loss for the year to March 2027, after it counted upfront fees for the Edesa EB05 licence and a second deal not yet signed.
Cancer drugs Enhertu and Datroway drove a 46.9% jump in Daiichi Sankyo's first-half core operating profit to ¥221.3bn, while only 30% of its healthcare unit has passed to Suntory Holdings, with control due to transfer in June 2027.
Nxera Pharma will receive $100mn upfront from AbbVie for a phase 1 bowel-disease drug, and it has fixed 2026 revenue guidance at ¥48.8bn, provided the deal closes by 31 December and its auditor agrees to the accounting.
Kissei's operating profit swung to ¥1.69bn from a ¥6.84bn loss in the half year, but impairment and inventory losses on assets tied to a drug facing approval proceedings cut net profit 33.3% and the full-year net profit guide to ¥10.0bn.
Astellas lifted its full-year core operating profit forecast to ¥700bn from ¥620bn after first-half sales rose 23.4%, though currency added ¥41.2bn to core profit and the new guide assumes a weaker yen than April's.
Kyowa Kirin books its half of the US KOMZIFTI profit-share with Kura Oncology as selling expense because the nine-month net result was negative, while currency and an Amgen contract release helped lift core operating profit 46.8%.
Otsuka Holdings lifted its year-to-December core profit forecast to ¥500bn from ¥470bn, with a newly launched IgA nephropathy drug and its antipsychotic offsetting a 31.1% nine-month sales fall in its kidney-disease drug after US generic entry.
Takeda's half-year net profit rose 171.6% on a 4.1% effective tax rate, yet core operating profit grew just 0.7% at constant currency, even as the drugmaker raised its full-year profit forecasts.
Kissei Pharmaceutical lifted its interim operating profit forecast to ¥1.6bn from ¥500mn, but cut net profit to ¥5.1bn from ¥7.4bn after factoring in special losses on assets for a drug facing approval-revocation proceedings.
Chugai Pharmaceutical's nine-month revenue rose 17.2%, with domestic sales helped by wholesaler shipments brought forward ahead of an ERP launch, yet full-year Core guidance of 6.9% revenue growth stays unchanged.
Seikagaku Corporation now expects a ¥1.8bn net loss for the year to March 2027, reversing a forecast ¥2.3bn profit, and has cut its full-year dividend from ¥30 to ¥20 per share after telling investors royalty income will fall sharply.
Kringle Pharma raised its annual sales guidance and narrowed its projected loss for the year to September 2026 after signing an exclusive Japan licensing deal with Maruishi Pharmaceutical for an experimental vocal-fold-scar treatment, under which it will record a ¥100 million upfront fee as revenue this fiscal year, with roughly half of the improved loss forecast coming instead from ¥108 million of development spending that shifted into next year.
SanBio's cell therapy for chronic traumatic brain injury, known by its development code SB623, cleared its final approval hurdle and reached the market in 2026 with a ¥72mn price tag, yet the company's latest results show no product revenue, a shrinking cash pile, and a 20.29% cut to capital to offset accumulated losses.
A ¥6.6bn reversal of Cullgen's preferred-share interest, not stronger drug sales, pushed GNI Group into the black for the first half, and the real growth test starts next quarter when Ayumi Pharmaceutical's revenue is added to the books.
A weaker yen added ¥60bn to Astellas Pharma's quarterly revenue and helped core operating profit jump 55.6% to ¥221.4bn, but strong sales of PADCEV and newer cancer drugs did the rest of the work, and the company is still not raising its full-year forecast.
Lenvima, Leqembi and Dayvigo again did the heavy lifting for Eisai's first quarter, with Leqembi's Americas sales up 71% masking a China pullback tied to last year's distributor stocking, while the drugmaker left its full-year targets exactly where it set them in May.
A string of drugmaker acquisitions, not stronger underlying sales, pushed Shionogi's quarterly net profit up 148% to ¥97.7bn, covering most of its own first-half profit guidance within three months while cutting its cash pile by more than half.
Enhertu and Datroway drove a 21.1% revenue jump for Daiichi Sankyo and prompted an upgraded sales and operating-profit outlook, yet a jump in the effective tax rate to 24.9% means the company actually cut its full-year net profit guidance by ¥9bn.
A weaker yen pushed Takeda's quarterly revenue up 10.2%, but at constant currency sales actually fell 0.5% and net profit dropped 23.5%, more than double the decline shown in headline yen figures, even as full-year targets and the dividend forecast held steady.
A slower-than-expected arrival of generic rivals for two of its drugs, plus a weaker yen, is pushing Otsuka Holdings' first-half net profit to ¥215bn, 68% above the guidance it issued in February.
Overseas shipments to majority owner Roche and royalty income from a licensed itch drug pushed Chugai's core profit up 23% in the first half, even as Japan's drug-price cuts dented older cancer medicines at home.
Hemlibra shipments to majority owner Roche and a sharp jump in Nemluvio exports to Galderma drove Chugai's core operating profit up 21% in the first half, while Japan's price controls kept domestic growth modest and management left its full-year guidance exactly where it stood in January.